Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,694.40 | 47.00 | -0.54% |
| CAC 40 | 7,553.45 | 102.67 | -1.34% |
| DAX 40 | 23,057.38 | 260.43 | -1.12% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,791.80 | 51.67 | -0.58% |
| HKSE | 23,419.76 | 182.02 | 0.78% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,445.57 | 42.77 | -0.11% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,473.50 | 50.20 | -0.59% |
| SSE Composite Index | 3,364.83 | 2.73 | 0.08% |